Key result
Serum IGF-I and total IGFBP-3 levels were significantly higher in individuals with impaired glucose tolerance and type 2 diabetes than in those with normal glucose tolerance (P<0.05).
Why the study?
Although insulin-like growth factor binding protein (IGFBP) plays an important role in glucose homeostasis, the IGF-independent role of IGFBP-3 in the glucose intolerance state is poorly understood.
Cross-Sectional (n=187)
p-value: p=<0.05
Serum IGF-I and total IGFBP-3 levels are elevated in children and adolescents with impaired glucose tolerance and type 2 diabetes, suggesting a role in the pathogenesis of glucose intolerance.
No immediate clinical implications for IGF assessment; cross-sectional data leaves open a pathogenic role in youth with glucose intolerance.
Insulin is important in glucose metabolism. However, insulin-like growth factor binding protein (IGFBP) also plays an important role in glucose homeostasis, although the IGF-independent role of IGFBP-3 in the glucose intolerance state is poorly understood. We investigated the relationship of serum IGF-I with total IGFBP-3 levels and glucose tolerance in Korean children and adolescents who underwent the oral glucose tolerance test (OGTT). A total of 187 children without known diabetes underwent OGTT, and data related to their clinical and laboratory parameters were collected. Serum IGF-I and total IGFBP-3 levels, fasting plasma glucose levels, lipid profiles, insulin levels, C-peptide levels, homeostasis model assessment of insulin resistance (HOMA-IR) index, and glycated hemoglobin (HbA1c) levels were measured. Serum IGF-I and total IGFBP-3 levels were significantly higher in individuals with impaired glucose tolerance and type 2 diabetes (DM) than in those with normal glucose tolerance (NGT) ( <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>P</a:mi> <a:mo><</a:mo> <a:mn>0.05</a:mn> </a:math> ). Serum IGF-I and IGFBP-3 levels were correlated with age, HbA1c, C-peptide, insulin, and HOMA-IR in the NGT group. However, these relationships were altered in patients with glucose intolerance, especially in those with DM. In the DM group, serum IGF-I and total IGFBP-3 levels were positively correlated with fasting plasma glucose and HbA1c levels. In addition, total IGFBP-3 levels were positively correlated with total cholesterol and low-density lipoprotein cholesterol and IGF-I levels but not with age or body mass index. The IGF-I-IGFBP-3 axis, especially IGFBP-3, may be involved in the pathogenesis and metabolic control of glucose intolerance, specifically in diabetes patients. Moreover, IGFBP-3 might be a therapeutic marker.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) conducted a cross-sectional in Glucose intolerance (n=187). Serum IGF-I and total IGFBP-3 levels vs. Normal glucose tolerance was evaluated on Glucose tolerance status and correlation with clinical and laboratory parameters (p=<0.05). Serum IGF-I and total IGFBP-3 levels were significantly higher in individuals with impaired glucose tolerance and type 2 diabetes than in those with normal glucose tolerance (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: